The First Longevity Vaccine
A senolytic vaccine targeting the cellular origin of atherosclerosis — and a hallmark of aging itself.
The Challenge
Atherosclerosis is the world's leading cause of death. The prevailing standard of care — statins — attempts to slow plaque formation. They do not remove existing plaques. They do not address the underlying biology. One in five deaths remains cardiac-related, and that number has not moved enough.
At Vertical Longevity Pharma, we believe this is unacceptable — and unnecessary. Unlike interventions that only delay the inevitable, our immunotherapy targets the cellular root cause, enabling the body to clear established plaques and recover naturally.
We are not managing disease.
We are ending it.
Mechanism
Our platform deploys a virus-like particle (VLP) to precisely target senescent cells — a cell type established in scientific literature as a key driver of both plaque formation and systemic aging. The result: a vaccine-mediated immune response that clears these cells durably.
Platform Breadth
Targeting the fundamental biology of cellular aging creates a ripple effect across the entire organism. Preclinical data reveals benefits beyond cardiovascular — a systems-level transformation.
Longevity for All
This is not a luxury intervention. Our financial projections position this senolytic vaccine cost-competitive with statins — while delivering multi-morbidity intervention capabilities that statins cannot.
Our platform can be manufactured in a thermostable formulation, enabling cold-chain-independent distribution to the most remote regions on Earth.
We anticipate cost reductions as manufacturing scales. Longevity intervention should not be a privilege of geography or wealth.
A single intervention addressing multiple age-related diseases simultaneously redefines the economics of preventive care at a population level.
Investor Overview
The cardiovascular therapeutics market is large, validated, and growing. VLP is entering with a mechanistically differentiated approach, preclinical proof-of-concept, and a PCT patent filing — at Series A stage.
Atherosclerosis and its downstream complications represent the largest single disease burden globally. Our addressable market spans primary prevention, secondary intervention, and aging co-morbidities.
The senolytic therapeutics space is nascent and rapidly accelerating. VLP is the first vaccine-based approaches to reach primate-stage validation — a significant first-mover advantage in a category defining the next decade of medicine.
Statins represent a $14B annual market. A therapy with double the efficacy, plaque clearance capability, and systemic aging benefits at competitive cost offers a compelling displacement thesis — not merely a differentiation story.
We are currently raising our Series A round. PCT patent filed. Preclinical efficacy demonstrated. Primate studies in progress. Early entry represents significant value creation opportunity ahead of IND filing and clinical stage milestones.
"A vaccine-based senolytic platform at Series A stage, with preclinical proof, primate validation underway, and a market spanning cardiovascular disease, aging, and longevity — represents one of the most asymmetric bets available in early-stage biotech."
Receive updates on clinical milestones, scientific publications, investor briefings, and the progress of the world's first senolytic atherosclerosis vaccine.
You're now on the list. We'll be in touch with meaningful updates only.